11/12/2021 PR
"Complete analysis of trial results already has begun, with the aim to potentially identify positive trends in the data that could support Brilacidin for inclusion in larger COVID-19 platform trials, such as the U.K.’s CTAP program and the NIH’s ACTIV program. The purpose of these programs is to prioritize development of promising COVID-19 therapeutics."
12/7/2021 PR
"The Company is pleased to report that as of last week it had received all unblinded data/data outputs from the recently completed Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients. The Innovation team is working with biostatistics partners to explore the data—conducting deeper analysis of different subgroups by patient demographics and baseline characteristics, domestic versus overseas COVID-19 standards of care, and more—to potentially identify meaningful patterns and positive trends. Analysis of the compassionate use of Brilacidin in the U.S. in critically-ill COVID-19 patients who had exhausted all other therapeutic options also is planned. Changes to biomarkers and positive clinical changes were observed, with some compassionate use patients administered Brilacidin more frequently and over a longer duration than patients in the Phase 2 Brilacidin COVID-19 trial. Collectively, these actions will help inform next steps for Brilacidin against COVID-19 in the coming year, while Brilacidin’s broad-spectrum antiviral properties continue to be researched through NIH and other scientific collaborations."
1/25/2022
"Upcoming Update on Brilacidin in COVID-19"
"Collaborative work with NIH and other researchers on Brilacidin’s broad-spectrum antiviral properties is ongoing and generating promising data, with future updates planned."
A common thread it the 2 PR's and the share holders letter are Brilacidin and the NIH
Could the promise of an update on Brilacidin in Covid 19 be in regards to the inclusion of Brilacidin in the NIH's fully funded ACTIV trial for Covid19 therapeutics?
You have to decide for yourself.
If Brilacidin is to be included in the fully funded ACTIV therapeutics trial IPIX's share price is much too low.
Stay tuned.
JMO
GLTA,
Farrell
